Envafolimab+Lenvatinib

Phase 2Small molecule

Envafolimab+Lenvatinib is one of 57 small molecule programs targeting Clear Cell Renal Cell Cancer (ccRCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clear Cell Renal Cell Cancer (ccrcc)Not yet recruiting

Endometrial CancerRecruiting

Clear Cell Renal Cell Cancer (ccrcc)Phase 2

Not yet recruiting

Endometrial CancerPhase 2

Recruiting

Competition

Competitive Landscape

103 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

53 2

Keytruda

Merck & Co.

Phase 3

21 3

Femara

Novartis

Phase 3

18 4

Paraplatin

AAvyxa

Phase 3

37 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

27 6

Megace

Bristol-Myers Squibb

Phase 3

10 7

Lenvima

Eisai

Phase 3

6 8

Lynparza

AstraZeneca

Phase 3

6 9

Depo-Provera

Eli Lilly

Phase 3

4 10

Tecentriq

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Endometrial Cancer

NCT05112991

Q2 2028

Phase 2Not yet recruiting

Clear Cell Renal Cell Cancer (ccrcc)

NCT07256223

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting·33D Medicines (Sichuan) Co., Ltd.·Phase 2·NCT05112991·108 enrolled

Clear Cell Renal Cell Cancer (ccRCC)1 trial

A Single-Arm, Multicenter, Prospective Clinical Study of Envafolimab Combined With Lenvatinib as First-Line Therapy in Renal Cell Carcinoma Patients With Liver Metastases

Not yet recruiting·FFudan University·Phase 2·NCT07256223·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Envafolimab+Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Envafolimab+Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Envafolimab+Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — 3D Medicines (Sichuan) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: 33D Medicines (Sichuan) Co., Ltd.

Envafolimab+Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Endometrial Cancer1 trial

Clear Cell Renal Cell Cancer (ccRCC)1 trial

References

Drug Info

Quick Facts

Related News